An observational study in Wilson Disease, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.
Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is the only one that started in 2026, is one of 6 observational ones, and was the 17th registered.
80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.
Browse Hepatolenticular Degeneration studies →8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 12+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–70
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+ · Healthy volunteers
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Orphalan · Sites in France, Belgium, Germany and 4 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: 7 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 72 across 35 observational studies indexed under Hepatolenticular Degeneration.
Median enrollment 40 across the 11 interventional studies, 150 across the 6 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 7 most frequent:
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
Fondation Ophtalmologique Adolphe de Rothschild has 7 studies filed under Hepatolenticular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatolenticular Degeneration with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430359Hospices Civils de LyonCircadian Variation of Urinary Copper Excretion in Wilson Disease Patients | 2027-02-10 |
| NCT05183165Fondation Ophtalmologique Adolphe de RothschildDescription of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease | 2027-03 |
| NCT05444127Fondation Ophtalmologique Adolphe de RothschildOral Health and Wilson's Disease: SOMAWI | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hepatolenticular Degeneration with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Wilson's disease (WD) is a rare genetic disorder that leads to copper accumulation in various tissues, including the liver, nervous system, heart, and kidneys. Renal involvement in WD has been poorly studied, and systematic screening is not currently recommended.
Indirect renal complications are the most common, such as hepatorenal and cardiorenal syndromes, as well as severe complications like hemolysis or rhabdomyolysis. However, literature suggests that copper may exert a direct toxic effect on renal tubular cells, leading to both proximal and distal tubular dysfunction. These may manifest through often subtle signs, such as aminoaciduria, glycosuria, hypouricemia, and low-molecular-weight proteinuria. Electrolyte imbalances of varying severity may also occur, including hypokalemia, which can cause muscle cramps and cardiac arrhythmias, as well as acid-base disorders (proximal or distal renal tubular acidosis), and/or phosphate-calcium metabolism abnormalities (phosphate diabetes and hypercalciuria). These latter issues may lead to complications such as urinary stones, nephrocalcinosis, and even fracture-related osteoporosis.
In addition, long-term treatment with D-penicillamine (DPA), a common therapy for WD, can cause renal damage in 10-20% of cases, mainly affecting the glomeruli. This includes membranous nephropathy, severe proliferative glomerulonephritis, or nephrotic syndrome with minimal change disease.
Without appropriate monitoring and preventive care, both direct and indirect renal complications can lead to acute or chronic kidney failure. It is likely that the prevalence and systemic impact of renal involvement in WD are currently underestimated.
Patients followed for Wilson disease accepting to undergo full renal workup (biology and echography)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients followed for wilson disease
Other: full renal workup
full renal workup (biology and echography)
Prevalence of renal involvement in Wilson's disease
Renal involvement is defined by the presence of at least one of the following criteria: * Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m² and/or proteinuria \> 0.5 g/g of creatinine. * Markers of proximal tubulopathy, defined by at least one of the following: phosphate diabetes (renal phosphate wasting), hypokalemia, normoglycemic glycosuria, β2-microglobulinuria, hypouricemia, or metabolic acidosis. * Hypercalciuria and/or urolithiasis.
Time frame: Day 0
Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Feb 2026 → Jul 2026, primary completion Feb 2027 → Jul 2029 and completion Feb 2027 → Jul 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hepatolenticular Degeneration →
Fondation Ophtalmologique Adolphe de Rothschild →